Focus on adoptive T cell transfer trials in melanoma

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Besser, Michal J ^a,b   Hershkovitz, Liat ^a   Schachter, Jacob ^a   Treves, Avraham J ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; LYMPHOCYTE ANTIGEN RECEPTOR; MELAN A; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; STEROID; T LYMPHOCYTE RECEPTOR; TUMOR CELL VACCINE;

ADOPTIVE T CELL TRANSFER; ADOPTIVE TRANSFER; ADVANCED CANCER; CANCER CENTER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CD8+ T LYMPHOCYTE; DRUG MEGADOSE; DRUG TARGETING; EX VIVO STUDY; GENETIC ENGINEERING; HEARING LOSS; HUMAN; LOW DRUG DOSE; LYMPHOCYTE TRANSFER; MELANOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UVEITIS; WHOLE BODY RADIATION; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METHODOLOGY; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 79952228946     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/260267     Document Type: Review

References (83)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008 (Pubitemid 351521864)
2. Tarhini A. A., Garwala S. S. A., Cutaneous melanoma: available therapy for metastatic disease Dermatologic Therapy 2006 19 1 19 25
3. Seam P., Janik J. E., Longo D. L., DeVita V. T., Role of chemotherapy in Hodgkin's lymphoma Cancer Journal 2009 15 2 150 154
4. Yang A. S., Chapman P. B., The history and future of chemotherapy for melanoma Hematology/Oncology Clinics of North America 2009 23 3 583 597
5. Bajetta E., Del Vecchio M., Bernard-Marty C., Vitali M., Buzzoni R., Rixe O., Nova P., Aglione S., Taillibert S., Khayat D., Metastatic melanoma: chemotherapy Seminars in Oncology 2002 29 5 427 445 (Pubitemid 35178282)
6. Serrone L., Zeuli M., Sega F. M., Cognetti F., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview Journal of Experimental and Clinical Cancer Research 2000 19 1 21 34 (Pubitemid 30305516)
7. Lotze M. T., Chang A. E., Seipp C. A., High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings Journal of the American Medical Association 1986 256 22 3117 3124 (Pubitemid 17045826)
8. Rosenberg S. A., Lotze M. T., Muul L. M., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer New England Journal of Medicine 1985 313 23 1485 1492 (Pubitemid 16212345)
9. Rosenberg S. A., Yang J. C., White D. E., Steinberg S. M., Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response Annals of Surgery 1998 228 3 307 319 (Pubitemid 30191694)
10. Atkins M. B., Kunkel L., Sznol M., Rosenberg S. A., High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update Cancer Journal from Scientific American 2000 6 supplement 1 S11 S14
11. Tsao H., Atkins M. B., Sober A. J., Management of cutaneous melanoma New England Journal of Medicine 2004 351 10 998 1042
12. Rosenberg S. A., Progress in human tumour immunology and immunotherapy Nature 2001 411 6835 380 384 (Pubitemid 32467048)
13. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J.M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebb C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma New England Journal of Medicine 2010 363 8 711 723
14. Senzer N. N., Kaufman H. L., Amatruda T., Nemunaitis M., Reid T., Daniels G., Gonzalez R., Glaspy J., Whitman E., Harrington K., Goldsweig H., Marshall T., Love C., Coffin R., Nemunaitis J. J., Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma Journal of Clinical Oncology 2009 27 34 5763 5771
15. Rosenberg S. A., Yang J. C., Restifo N. P., Cancer immunotherapy: moving beyond current vaccines Nature Medicine 2004 10 9 909 915 (Pubitemid 39273730)
16. Besser M. J., Shapira-Frommer R., Treves A. J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., Shalmon B., Hardan I., Catane R., Markel G., Apter S., Ben-Nun A., Kuchuk I., Shimoni A., Nagler A., Schachter J., Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clinical Cancer Research 2010 16 9 2646 2655
17. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma Journal of Clinical Oncology 2005 23 10 2346 2357 (Pubitemid 46218728)
18. Dudley M. E., Yang J. C., Sherry R., Hughes M. S., Royal R., Kammula U., Robbins P. F., Huang J., Citrin D. E., Leitman S. F., Wunderlich J., Restifo N. P., Thomasian A., Downey S. G., Smith F. O., Klapper J., Morton K., Laurencot C., White D. E., Rosenberg S. A., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens Journal of Clinical Oncology 2008 26 32 5233 5239
19. Mule J. J., Shu S., Schwarz S. L., Rosenberg S. A., Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2 Science 1984 225 4669 1487 1489 (Pubitemid 14033135)
20. Muul L. M., Nason-Burchenal K., Carter C. S., Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy Journal of Immunological Methods 1987 101 2 171 181 (Pubitemid 17097911)
21. Mesler Muul L., Nason-Burchenal K., Hyatt C., Schwarz S., Slavin D., Director E. P., Rosenberg S. A., Studies of serum-free culture medium in the generation of lymphokine activated killer cells Journal of Immunological Methods 1987 105 2 183 192 (Pubitemid 18015301)
22. Rosenberg S. A., Lotze M. T., Yang J. C., Topalian S. L., Chang A. E., Schwartzentruber D. J., Aebersold P., Leitman S., Linehan W. M., Seipp C. A., White D. E., Steinberg S. M., Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer Journal of the National Cancer Institute 1993 85 8 622 632 (Pubitemid 23120507)
23. Dudley M. E., Rosenberg S. A., Adoptive cell transfer therapy Seminars in Oncology 2007 34 6 524 531 (Pubitemid 350236303)
24. Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2 Journal of the National Cancer Institute 1994 86 15 1159 1166 (Pubitemid 24249302)
25. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A., Simpson C., Carter C., Bock S., Schwartzentruber D., Wei J. P., White D. E., Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report New England Journal of Medicine 1988 319 25 1676 1680 (Pubitemid 19015247)
26. Rosenberg S. A., Aebersold P., Cornetta K., Kasid A., Morgan R. A., Moen R., Karson E. M., Lotze M. T., Yang J. C., Topalian S. L., Merino M. J., Culver K., Miller A. D., Blaese R. M., Anderson W. F., Gene transfer into humans-Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction New England Journal of Medicine 1990 323 9 570 578 (Pubitemid 20260084)
27. Schwartzentruber D. J., Hom S. S., Dadmarz R., White D. E., Yannelli J. R., Steinberg S. M., Rosenberg S. A., Topalian S. L., In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2 Journal of Clinical Oncology 1994 12 7 1475 1483 (Pubitemid 24206248)
28. Aebersold P., Hyatt C., Johnson S., Hines K., Korcak L., Sanders M., Lotze M., Topalian S., Yang J., Rosenberg S. A., Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response Journal of the National Cancer Institute 1991 83 13 932 937
29. Kirkwood J. M., Tarhini A. A., Panelli M. C., Moschos S. J., Zarour H. M., Butterfield L. H., Gogas H. J., Next generation of immunotherapy for melanoma Journal of Clinical Oncology 2008 26 20 3445 3455
30. Kawakami Y., Zakut R., Topalian S. L., Stotter H., Rosenberg S. A., Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas Journal of Immunology 1992 148 2 638 643
31. Hom S. S., Topalian S. L., Simonis T., Mancini M., Rosenberg S. A., Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction Journal of Immunotherapy 1991 10 3 153 164
32. Darrow T. L., Slingluff C. L., Seigler H. F., The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens Journal of Immunology 1989 142 9 3329 3335 (Pubitemid 19129962)
33. Schwartzentruber D. J., Topalian S. L., Mancini M., Rosenberg S. A., Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-, and IFN- by human tumor-infiltrating lymphocytes after autologous tumor stimulation Journal of Immunology 1991 146 10 3674 3681
34. Schwartzentruber D. J., Solomon D., Rosenberg S. A., Topalian S. L., Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion Journal of Immunotherapy 1992 12 1 1 12
35. Hom S. S., Schwartzentruber D. J., Rosenberg S. A., Topalian S. L., Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens Journal of Immunotherapy 1993 13 1 18 30 (Pubitemid 23011931)
36. Besser M. J., Shapira-Frommer R., Treves A. J., Zippel D., Itzhaki O., Schallmach E., Kubi A., Shalmon B., Hardan I., Catane R., Segal E., Markel G., Apter S., Nun A. B., Kuchuk I., Shimoni A., Nagler A., Schachter J., Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients Journal of Immunotherapy 2009 32 4 415 423
37. Dudley M. E., Wunderlich J. R., Shelton T. E., Even J., Rosenberg S. A., Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients Journal of Immunotherapy 2003 26 4 332 342 (Pubitemid 36858717)
38. Besser M. J., Treves A. J., Itzhaki O., Hardan I., Nagler A., Papa M. Z., Catane R., Winkler E., Shalmon-Zifroni B., Schachter J., Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center Israel Medical Association Journal 2006 8 3 164 168
39. Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A. T., Christian M. C., Gwyther S. G., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Journal of the National Cancer Institute 2000 92 3 205 216
40. Muranski P., Boni A., Wrzesinski C., Citrin D. E., Rosenberg S. A., Childs R., Restifo N. P., Increased intensity lymphodepletion and adoptive immunotherapyhow far can we go? Nature Clinical Practice Oncology 2006 3 12 668 681 (Pubitemid 44843125)
41. Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002 298 5594 850 854 (Pubitemid 35231542)
42. Zhou J., Shen X., Huang J., Hodes R. J., Rosenberg S. A., Robbins P. F., Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy Journal of Immunology 2005 175 10 7046 7052 (Pubitemid 41598952)
43. Shen X., Zhou J., Hathcock K. S., Robbins P., Powell D. J., Rosenberg S. A., Hodes R. J., Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length Journal of Immunotherapy 2007 30 1 123 129 (Pubitemid 46052211)
44. Robbins P. F., Dudley M. E., Wunderlich J., El-Gamil M., Li Y. F., Zhou J., Huang J., Powell D. J., Rosenberg S. A., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy Journal of Immunology 2004 173 12 7125 7130 (Pubitemid 39628146)
45. Tran K. Q., Zhou J., Durflinger K. H., Langhan M. M., Shelton T. E., Wunderlich J. R., Robbins P. F., Rosenberg S. A., Dudley M. E., Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy Journal of Immunotherapy 2008 31 8 742 751
46. Powell D. J., Dudley M. E., Robbins P. F., Rosenberg S. A., Transition of late-stage effector T cells to CD27 CD28 tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy Blood 2005 105 1 241 250 (Pubitemid 40053089)
47. Antony P. A., Piccirillo C. A., Akpinarli A., Finkelstein S. E., Speiss P. J., Surman D. R., Palmer D. C., Chan C. C., Klebanoff C. A., Overwijk W. W., Rosenberg S. A., Restifo N. P., CD8 T cell immunity against a tumor/self-antigen is augmented by CD4 T helper cells and hindered by naturally occurring T regulatory cells Journal of Immunology 2005 174 5 2591 2601 (Pubitemid 40279672)
48. Dummer W., Niethammer A. G., Baccala R., Lawson B. R., Wagner N., Reisfeld R. A., Theofilopoulos A. N., T cell homeostatic proliferation elicits effective antitumor autoimmunity Journal of Clinical Investigation 2002 110 2 185 192 (Pubitemid 34787355)
49. Gattinoni L., Finkelstein S. E., Klebanoff C. A., Antony P. A., Palmer D. C., Spiess P. J., Hwang L. N., Yu Z., Wrzesinski C., Heimann D. M., Surh C. D., Rosenberg S. A., Restifo N. P., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 T cells Journal of Experimental Medicine 2005 202 7 907 912 (Pubitemid 41396891)
50. Wrzesinski C., Paulos C. M., Gattinoni L., Palmer D. C., Kaiser A., Yu Z., Rosenberg S. A., Restifo N. P., Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells Journal of Clinical Investigation 2007 117 2 492 501 (Pubitemid 46203978)
51. Theobald M., Biggs J., Hernndez J., Lustgarten J., Labadie C., Sherman L. A., Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes Journal of Experimental Medicine 1997 185 5 833 841 (Pubitemid 27119867)
52. Romieu R., Baratin M., Kayibanda M., Lacabanne V., Ziol M., Guillet J. G., Viguier M., Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model Journal of Immunology 1998 161 10 5133 5137 (Pubitemid 28519068)
53. Murphy A., Westwood J. A., Teng M. W. L., Moeller M., Darcy P. K., Kershaw M. H., Gene modification strategies to induce tumor immunity Immunity 2005 22 4 403 414 (Pubitemid 40545107)
54. Sadelain M., Rivire I., Brentjens R., Targeting tumours with genetically enhanced T lymphocytes Nature Reviews Cancer 2003 3 1 35 45 (Pubitemid 37328885)
55. Sadelain M., Brentjens R., Rivire I., The promise and potential pitfalls of chimeric antigen receptors Current Opinion in Immunology 2009 21 2 215 223
56. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalan S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 5796 126 129 (Pubitemid 44547756)
57. Theoret M. R., Cohen C. J., Nahvi A. V., Ngo L. T., Suri K. B., Powell D. J., Dudley M. E., Morgan R. A., Rosenberg S. A., Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells Human Gene Therapy 2008 19 11 1219 1231
58. Robbins P. F., Li Y. F., El-Gamil M., Zhao Y., Wargo J. A., Zheng Z., Xu H., Morgan R. A., Feldman S. A., Johnson L. A., Bennett A. D., Dunn S. M., Mahon T. M., Jakobsen B. K., Rosenberg S. A., Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions Journal of Immunology 2008 180 9 6116 6131
59. Parkhurst M. R., Joo J., Riley J. P., Yu Z., Li Y., Robbins P. F., Rosenberg S. A., Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells Clinical Cancer Research 2009 15 1 169 180
60. Johnson L. A., Morgan R. A., Dudley M. E., Cassard L., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Sherry R. M., Wunderlich J. R., Lee C. C. R., Restifo N. P., Schwarz S. L., Cogdill A. P., Bishop R. J., Kim H., Brewer C. C., Rudy S. F., VanWaes C., Davis J. L., Mathur A., Ripley R. T., Nathan D. A., Laurencot C. M., Rosenberg S. A., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 2009 114 3 535 546
61. Eshhar Z., Waks T., Gross G., Schindler D. G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the or subunits of the immunoglobulin and T-cell receptors Proceedings of the National Academy of Sciences of the United States of America 1993 90 2 720 724 (Pubitemid 23028937)
62. Till B. G., Jensen M. C., Wang J., Chen E. Y., Wood B. L., Greisman H. A., Qian X., James S. E., Raubitschek A., Forman S. J., Gopal A. K., Pagel J. M., Lindgren C. G., Greenberg P. D., Riddell S. R., Press O. W., Adoptive immunotherapy for indolent non-hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 2008 112 6 2261 2271
63. Lamers C. H., Sleijfer S., Vulto A. G., Kruit W. H., Kliffen M., Debets R., Gratama J. W., Stoter G., Oosterwijk E., Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience Journal of Clinical Oncology 2006 24 13 e20 e22
64. Kershaw M. H., Westwood J. A., Parker L. L., Wang G., Eshhar Z., Mavroukakis S. A., White D. E., Wunderlich J. R., Canevari S., Rogers-Freezer L., Chen C. C., Yang J. C., Rosenberg S. A., Hwu P., A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clinical Cancer Research 2006 12 20, part 1 6106 6115 (Pubitemid 44703776)
65. Maher J., Brentjens R. J., Gunset G., Rivire I., Sadelain M., Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR /CD28 receptor Nature Biotechnology 2002 20 1 70 75 (Pubitemid 34044918)
66. Hombach A., Heuser C., Marquardt T., Wieczarkowiecz A., Groneck V., Pohl C., Abken H., CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion Journal of Immunology 2001 167 2 1090 1096 (Pubitemid 32660869)
67. Haynes N. M., Trapani J. A., Teng M. W. L., Jackson J. T., Cerruti L., Jane S. M., Kershaw M. H., Smyth M. J., Darcy P. K., Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors Blood 2002 100 9 3155 3163 (Pubitemid 35217063)
68. Gross G., Waks T., Eshhar Z., Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proceedings of the National Academy of Sciences of the United States of America 1989 86 24 10024 10028 (Pubitemid 20030768)
69. Yvon E., Del Vecchio M., Savoldo B., Hoyos V., Dutour A., Anichini A., Dotti G., Brenner M. K., Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells Clinical Cancer Research 2009 15 18 5852 5860
70. Yun C. O., Nolan K. F., Beecham E. J., Reisfeld R. A., Junghans R. P., Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin t-cell receptors Neoplasia 2000 2 5 449 459 (Pubitemid 32044791)
71. Willemsen R. A., Ronteltap C., Chames P., Debets R., Bolhuis R. L. H., T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production Journal of Immunology 2005 174 12 7853 7858 (Pubitemid 40806294)
72. Morgan R. A., Yang J. C., Kitano M., Dudley M. E., Laurencot C. M., Rosenberg S. A., Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2 Molecular Therapy 2010 18 4 843 851
73. Gattinoni L., Klebanoff C. A., Palmer D. C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S. E., Theoret M. R., Rosenberg S. A., Restifo N. P., Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells Journal of Clinical Investigation 2005 115 6 1616 1626 (Pubitemid 40814670)
74. Klebanoff C. A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A. R., Finkelstein S. E., Palmer D. C., Antony P. A., Hwang S. T., Rosenberg S. A., Waldmann T. A., Restifo N. P., Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells Proceedings of the National Academy of Sciences of the United States of America 2005 102 27 9571 9576 (Pubitemid 40981722)
75. Huang J., Khong H. T., Dudley M. E., El-Gamil M., Li Y. F., Rosenberg S. A., Robbins P. F., Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression Journal of Immunotherapy 2005 28 3 258 267 (Pubitemid 40593992)
76. Huang J., Kerstann K. W., Ahmadzadeh M., Li Y. F., El-Gamil M., Rosenberg S. A., Robbins P. F., Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy Journal of Immunology 2006 176 12 7726 7735 (Pubitemid 43849073)
77. Refaeli Y., Van Parijs L., London C. A., Tschopp J., Abbas A. K., Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis Immunity 1998 8 5 615 623 (Pubitemid 28264752)
78. Pouw N., Treffers-Westerlaken E., Kraan J., Wittink F., Ten Hagen T., Verweij J., Debets R., Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells Cancer Immunology, Immunotherapy 2010 59 6 921 931
79. Jaleco S., Swainson L., Dardalhon V., Burjanadze M., Kinet S., Taylor N., Homeostasis of naive and memory CD4 T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis Journal of Immunology 2003 171 1 61 68 (Pubitemid 36745273)
80. Hinrichs C. S., Spolski R., Paulos C. M., Gattinoni L., Kerstann K. W., Palmer D. C., Klebanoff C. A., Rosenberg S. A., Leonard W. J., Restifo N. P., IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy Blood 2008 111 11 5326 5333
81. Oved K., Eden E., Akerman M., Noy R., Wolchinsky R., Izhaki O., Schallmach E., Kubi A., Zabari N., Schachter J., Alon U., Mandel-Gutfreund Y., Besser M. J., Reiter Y., Predicting and controlling the reactivity of immune cell populations against cancer Molecular Systems Biology 2009 5, article 265
82. Yee C., Thompson J. A., Byrd D., Riddell S. R., Roche P., Celis E., Greenberg P. D., Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proceedings of the National Academy of Sciences of the United States of America 2002 99 25 16168 16173 (Pubitemid 35462767)
83. Yang J. C., Sherry R. M., Steinberg S. M., Topalian S. L., Schwartzentruber D. J., Hwu P., Seipp C. A., Rogers-Freezer L., Morton K. E., White D. E., Liewehr D. J., Merino M. J., Rosenberg S. A., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer Journal of Clinical Oncology 2003 21 16 3127 3132 (Pubitemid 46606294